Proptosis non-responders who have completed the treatment period may choose to enter an open-label extension period where they will receive eight infusions of TEPEZZA. More information about the trial, including full eligibility criteria, can be found at clinicaltrials.gov ( NCT04583735 ). "Thyroid Eye Disease is complex and changes over time, presenting unique challenges at every stage," said Elizabeth H.Z. Thompson, Ph.D., executive vice president, research and development, Horizon. "We have spoken with many patients who continue to struggle with difficult symptoms well into the chronic phase. TEPEZZA is indicated for Thyroid Eye Disease, which includes both acute and chronic phases, and this trial will expand our understanding of the role it can play in helping people living with chronic disease."